Related Experiment Videos
Potential for selective modulation of glutathione in cancer chemotherapy
X Chen1, G D Carystinos, G Batist
1Department of Experimental Medicine, McGill University, Montreal, QC, Canada.
Abstract:
Notwithstanding ongoing progress in anticancer therapeutics development, the persistent problem remains to selectively target tumors while sparing normal tissues. This is confounding largely because the differences between normal and tumor cells are often subtle and part of a gradient, where a gene product may be more or less expressed in tumor compared with the host normal tissue, but seldom expressed (or turned off) in tumors. The role of glutathione (GSH) and related enzymes in cellular resistance to xenobiotics, including chemotherapy is well established. This study is among those attempting to modulate GSH to therapeutic advantage. The authors briefly describe the experience with the gamma-glutamylcysteine synthetase inhibitor buthionine sulfoximine, and then in greater detail outline recent evidence for a potentially more selective approach using the cysteine prodrug L-2-oxothiazolidine-4-carboxylate. This has led to a detailed study of the activating enzyme 5-oxo-L-prolinase, including enzymatic and immunocharacterization, as well as in vitro study of the effect of its modulators on anticancer drug toxicity. Using high affinity antibodies the authors have generated interesting information on the distribution of this enzyme in tumor versus normal human tissues. Finally, the authors have been studying the potential for modulating gap junctions as a part of anti-cancer therapeutics, since they transport GSH between cells and are generally deficient in tumor cells. Preliminary studies suggest that gap junction induction may dramatically deplete GSH concentration in tumor cells and sensitize them to a variety of treatments.
Insights
Targeting tumors selectively remains challenging. This study explores modulating glutathione (GSH) levels using novel compounds and gap junction modulation to enhance anticancer drug efficacy and reduce toxicity in cancer therapy.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Selective tumor targeting is a persistent challenge in anticancer therapeutics.
- Glutathione (GSH) and related enzymes play a key role in cellular resistance to chemotherapy.
- Differences in gene expression between normal and tumor cells are often subtle, complicating targeted therapies.
Purpose of the Study:
- To explore novel strategies for modulating glutathione (GSH) to enhance anticancer therapeutic efficacy.
- To investigate the potential of L-2-oxothiazolidine-4-carboxylate and its activating enzyme, 5-oxo-L-prolinase, for selective tumor targeting.
- To assess the role of gap junctions in GSH transport and their potential as a therapeutic target in cancer.
Main Methods:
- Enzymatic and immunocharacterization of 5-oxo-L-prolinase.
- In vitro studies on the effect of 5-oxo-L-prolinase modulators on anticancer drug toxicity.
- Investigation of gap junction modulation for altering intracellular GSH levels in tumor cells.
Main Results:
- Characterization of 5-oxo-L-prolinase and its distribution in human tumor versus normal tissues.
- Preliminary evidence suggests that modulating gap junctions can deplete tumor cell GSH and sensitize them to treatments.
- L-2-oxothiazolidine-4-carboxylate shows potential as a more selective approach compared to buthionine sulfoximine.
Conclusions:
- Modulating glutathione (GSH) metabolism and transport presents a promising avenue for improving anticancer therapeutics.
- Targeting 5-oxo-L-prolinase and gap junctions offers potential for selective tumor sensitization.
- Further research into these mechanisms could lead to more effective and less toxic cancer treatments.